The present disclosure relates to an implant component (10, 20) having at least one connecting portion (30, 60), the connecting portion being at least partly coated with a Zr coating and the coating having a thickness of 1-20 μm, preferably 1-6 μm. The present disclosure further relates to a modular endoprosthesis comprising an implant component, to the use of a Zr coating to prevent crevice corrosion and/or fretting corrosion, and to the use of an implant component in patients suffering from a metal allergy.

System and methods for stimulating cartilage formation at a first tissue site through a second tissue site is presented. The system includes a fluid source for supplying a therapeutic solution, a reduced pressure source for supplying reduced pressure, a fluid delivery manifold for deploying adjacent the first tissue site, and a vacuum manifold for deploying within the second tissue site. The fluid delivery manifold extends between a proximal end fluidly coupled to the fluid supply and a distal end having at least one aperture for delivering the therapeutic solution to the defect adjacent the articulating surface of the first tissue site. The vacuum manifold extends between a proximal end fluidly coupled to the reduced pressure source and a distal end having at least one aperture for delivering the reduced pressure to the first tissue site adjacent the opposing surface of the first tissue site.

This disclosure is directed to methods for reconstructing an unstable triangular fibrocartilage complex (TFCC). Exemplary methods include preparing, delivering, and fixating a graft within a distal radioulnar joint in a manner that restores the functionality to the TFCC, thereby improving the joint kinematics of the radioulnar joint.

The subject matter of the invention is an autopolymerisable 2-component prosthetic base material, a kit containing the material as well as a method for its production comprising at least one liquid monomer component (A), and at least one powdered component (B), wherein the prosthetic material in component (A) besides methylmethacrylate contains at least one N-alkyl-substituted acryloyloxy carbamate having a molecular mass of less than or equal to 250 g/mol, optionally at least one at least di-functional urethane (meth)acrylate, a di-, tri-, tetra- or multi-functional monomer not being urethane (meth)acrylate, and optionally polymeric particles having a primary particle size of less than 800 nm, and the powdered component (B) comprises polymeric particles having at least three different particle size fractions, and both (A) and (B) contains at least one initiator or at least one component of an initiator system for autopolymerisation.

The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

A joint dislocation reduction device includes an elongated flexible ribbon-like band extending along a central axis from a proximal end to a tapered distal end. A distal end coupling element is disposed at the distal end. A proximal end coupling element is disposed at the proximal end. A cord extends from the tapered distal end to a needle. In a form, the band includes a flexible metallic ribbon disposed within a surrounding flexible, insulating coating element, wherein the band includes one or more resilient shape-memory regions between the proximal and distal ends. With the band under applied axial tension, the proximal end and distal end coupling elements are adapted to form a coupling assembly coupling the proximal and distal ends, forming a closed loop around a clavicle and a coracoid process with a single 180° twist, whereby the band rests flush against the clavicle and the coracoid process.

The data presented herein relates to therapeutic compositions of mesenchymal stem cells (MSCs). In particular, pharmaceutically acceptable MSC compostions are xenogen-free and do not have immunological adverse effects. Mesenchymal stem cells expanded in a cell culture media comprising bone marrow supernatant produce xenogen-free mesenchymal stem cells. Such xenogen-free MSC compositions improve therapy for medical conditions including, but not limited to, osteoarthritis, cardiovascular disorders and/or diabetes.

A biocompatible implant according to one aspect of the present disclosure includes a base and a calcium phosphate coating film located on a surface of the base and including silver. The calcium phosphate coating film includes a plurality of calcium phosphate particles located on a surface thereof, and a plurality of needle-like crystals located on a surface of the plurality of calcium phosphate and the plurality of needle-like crystals are located in a gap at an interface between adjacent calcium phosphate particles among the plurality of calcium phosphate particles.

Described herein are dehydrated, laminated tissue grafts composed of two or more membrane layers of an amnion membrane, a chorion membrane, a Wharton's jelly, or an intermediate tissue layer, where a layer of micronized placental tissue is interposed between two of the layers. Also described herein are methods for making and using the laminated tissue grafts.

Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.